Y-27632

Y-27632

SCHEMBL1980406

C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 8/20 1.00
ROCK1 Q13464 8/20 1.00
PKN2 Q16513 4/20 1.00
RPS6KA5 O75582 3/20 1.00
LRRK2 Q5S007 3/20 1.00
TP53 P04637 2/20 1.00
CYP3A4 P08684 2/20 1.00
PRKD3 O94806 2/20 1.00
CDK1 P06493 2/20 1.00
CDK2 P24941 2/20 1.00
LTK P29376 2/20 1.00
CDK8 P49336 2/20 1.00
PRKX P51817 2/20 1.00
PRKCQ Q04759 2/20 1.00
PRKCD Q05655 2/20 1.00
STK3 Q13188 2/20 1.00
CDC42BPA Q5VT25 2/20 1.00
BRSK1 Q8TDC3 2/20 1.00
CLK4 Q9HAZ1 2/20 1.00
TSHR P16473 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Y-27632 SCHEMBL28416532 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL598993 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL190356 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL20333114 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL18935698 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL342816 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL30286315 1.00 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL2796890 0.99 ROCK2 (0.97) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL1554110 0.99 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2
Y-27632 SCHEMBL2834049 0.99 ROCK2 (1.00) ROCK2ROCK1PKN2RPS6KA5LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099481-A1 METHOD FOR PRODUCING CELLS HAVING AN ACINAR CELL PHENOTYPE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-05-15 WO claimed
EP-3350313-B1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2025-11-26 EP claimed
US-12428623-B2 Generation of midbrain-specific organoids from human pluripotent stem cells AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-09-30 US claimed
EP-4602150-A1 A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS Eyestem Research Private Limited (IN) 2025-08-20 EP claimed
US-20250241964-A1 SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS EYESTEM RESEARCH PRIVATE LIMITED (IN) 2025-07-31 US claimed
US-20250243467-A1 BONE MARROW ORGANOIDS PRODUCED FROM INDUCED PLURIPOTENT STEM CELLS AND USES OF THESE ORGANOIDS Prism Ingenuity GmbH (DE) 2025-07-31 US claimed
US-12371664-B2 Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby CHA BIOTECH CO., LTD. (KR) 2025-07-29 US claimed
CN-120019141-A Scalable method for generating Retinal Pigment Epithelial (RPE) cells 艾视泰研究私人有限公司 2025-05-16 CN claimed
US-20250154472-A1 Culture Medium for Expanding Breast Epithelial Stem Cells KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) 2025-05-15 US claimed
EP-4504908-A1 BONE MARROW ORGANOIDS PRODUCED FROM INDUCED PLURIPOTENT STEM CELLS AND USES OF THESE ORGANOIDS Prism Ingenuity GmbH (DE) 2025-02-12 EP claimed
EP-3047018-A1 CORNEAL STROMAL KERATOCYTE CULTURE Singapore Health Services Pte Ltd (SG) 2016-07-27 EP claimed
EP-3043822-A1 COMPOSITIONS FOR PREPARING CARDIOMYOCYTES The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) 2016-07-20 EP claimed
US-20160186141-A1 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad 2016-06-30 US claimed
EP-3006028-A1 COMPOSITION FOR REDUCING CELL SENESCENCE COMPRISING RHO-KINASE INHIBITOR AND USE THEREOF Samsung Electronics Co., Ltd (KR) 2016-04-13 EP claimed
US-20160095864-A1 COMPOSITION FOR REDUCING CELL SENESCENCE COMPRISING RHO-KINASE INHIBITOR AND USE THEREOF SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-04-07 US claimed
US-20160031837-A1 COMPOUNDS FOR INDUCING PROLIFERATION AND DIFFERENTIATION OF CELLS, AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. (US) 2016-02-04 US claimed
WO-2015041606-A1 CORNEAL STROMAL KERATOCYTE CULTURE SINGAPORE HEALTH SERVICES PTE LTD (SG) 2015-03-26 WO claimed
WO-2015038704-A1 COMPOSITIONS FOR PREPARING CARDIOMYOCYTES THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) 2015-03-19 WO claimed
US-8883502-B2 Expandable cell source of neuronal stem cell populations and methods for obtaining and using them THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-11 US claimed
US-20130236436-A1 EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM ZHANG KANG (US) 2013-09-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160186141-A1 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES MYLK2, TNNI3, TNNT2 ROCK2 90/4885ROCK1 186/4885PKN2 1630/4885
US-20160031837-A1 COMPOUNDS FOR INDUCING PROLIFERATION AND DIFFERENTIATION OF CELLS, AND METHODS OF USE THEREOF HGF, HDGF, CD14 ROCK2 206/4885ROCK1 209/4885PKN2 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.